Sign up to save your podcasts
Or
Share In spite of plummeting valuation, 23andMe still aims to pivot into biotech
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
In spite of plummeting valuation, 23andMe still aims to pivot into biotech
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
View all episodes
By Marketplace
4.5
12471,247 ratings
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
More shows like Marketplace Tech
View all
Freakonomics Radio
32,034 Listeners
Planet Money
30,727 Listeners
Marketplace
8,764 Listeners
Marketplace Morning Report
926 Listeners
Marketplace All-in-One
1,390 Listeners
WSJ Your Money Briefing
1,708 Listeners
WSJ What’s News
4,327 Listeners
The Uncertain Hour
2,179 Listeners
Make Me Smart
5,493 Listeners
Up First from NPR
56,489 Listeners
Bold Names
1,446 Listeners
The Indicator from Planet Money
9,535 Listeners
This Is Uncomfortable
3,586 Listeners
Fiction - Comedy Fiction
6,444 Listeners
Consider This from NPR
6,395 Listeners
Marketplace Minute
163 Listeners
Million Bazillion
2,997 Listeners
Hard Fork
5,522 Listeners
How We Survive
1,378 Listeners
Financially Inclined
90 Listeners